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Key Points
• The combination of rituximab,
lenalidomide, and ibrutinib is
associated with a high
incidence of rash in follicular
lymphoma (all grades 82%).
• Efficacy of the triplet
appears similar to rituximab-
lenalidomide in the same
patient population.
Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity.
Targeted therapies are being investigated as potentially more efficacious and tolerable
alternatives for this multiply-relapsing disease. Based on promising activity with
rituximab and lenalidomide in previously untreated follicular lymphoma (overall re-
sponse rate [ORR] 90%-96%) and ibrutinib in relapsed disease (ORR 30%-55%), the
Alliance for Clinical Trials in Oncology conducted a phase 1 trial of rituximab,
lenalidomide, and ibrutinib. Previously untreated patients with follicular lymphoma
received rituximab 375mg/m2 on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 4, 6, 8,
and10; lenalidomideasper cohort doseondays1 to21of 28 for 18 cycles; and ibrutinibas
per cohort dose daily until progression. Dose escalation used a 313 design from a
starting dose level (DL) of lenalidomide 15 mg and ibrutinib 420 mg (DL0) to DL2
(lenalidomide 20 mg, ibrutinib 560 mg). Twenty-two patients were enrolled; DL2 was
determined to be the recommended phase II dose. Although no protocol-defined dose-
limiting toxicitieswere reported, a high incidence of rashwas observed (all grades 82%, grade 3 36%). Eleven patients (50%) required
dose reduction, 7 because of rash. TheORR for the entire cohort was 95%, and the 12-month progression-free survival was 80% (95%
confidence interval, 57%-92%). Five patients developed new malignancies; 3 had known risk factors before enrollment. Given the
increased toxicity and required dose modifications, as well as the apparent lack of additional clinical benefit to the rituximab-
lenalidomide doublet, further investigation of the regimen in this setting seems unwarranted. The study was registered with www.
ClinicalTrials.gov as #NCT01829568. (Blood. 2016;128(21):2510-2516)
Introduction
The standard approach for the treatment of advanced-stage follicular
lymphoma, themost common of the indolent non-Hodgkin lymphomas
(NHL), has traditionally consisted of chemoimmunotherapy. Although
regimens such as R-CHOP (rituximab, cyclophosphamide, vincristine,
prednisone) and BR (bendamustine, rituximab) achieve overall re-
sponse rates (ORR) of .90% in the front-line setting, patients
inevitably relapse.1-4 Furthermore, these regimens are associated
with acute and long-term toxicity, including but not limited to
infection, myelosuppression, and neuropathy. Given the growing
number of novel therapies with unique mechanisms of action, a
multitargeted biological regimenmay improve outcomeswith fewer,
less severe adverse events in this otherwise incurable disease.
The Alliance for Clinical Trials in Oncology group, which includes
the former Cancer and Leukemia Group B (CALGB), previously
demonstrated the efficacy of the combination of rituximab and
lenalidomide in follicular lymphoma. The CALGB 50401 phase
2 study reported an ORR of 76% (complete response [CR] 39%) and a
2-year time-to-progression of 52% in patients with relapsed disease.5
Preliminary data from the CALGB 50803 study indicated greater
activity with the doublet in the front-line setting. Patients received
rituximab 375mg/m2 (cycle 1, days 1, 8, 15, and 22; cycles 4, 6, 8, and
10, day 1) and lenalidomide 20 mg (days 1-21 for twelve 28-day cy-
cles), resulting in an ORR of 96% and a CR rate of 71%.6 An
additional 6% achieved a CR by restaging 18FDG PET-CT scans
(fluoro-deoxyglucose positron emission tomography combined with
computed tomography), but were not included in the reported CR
rate becase of lack of confirmatory bone marrow biopsies. The 2-year
progression-free survival (PFS)was89%among the65patients enrolled.
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Fowler et al noted similar response rates in a single-institution study,with
a 3-year PFS of 79%.7 These impressive data supported the develop-
ment of the phase 3 RELEVANCE trial of rituximab-lenalidomide vs
rituximab-based chemoimmunotherapy (NCT01476787), which com-
pleted accrual in 2015.
The Alliance sought to improve upon the efficacy of rituximab-
lenalidomide with the addition of a B-cell receptor antagonist (BCR),
ibrutinib.Afirst-in-class, selective, irreversible inhibitorofBruton tyrosine
kinase (BTK), ibrutinib is approved in chronic lymphocytic leukemia
(CLL),mantle cell lymphoma, andWaldenstro¨mmacroglobulinemia. As
a singleagent, it hasproducedORRsof30%to55%inearly-phaseclinical
trials of heavily pretreated patients with relapsed and refractory follicular
lymphoma.8-10 Ibrutinibmonotherapy is associatedwithminimal toxicity;
the most common adverse events are mild edema, diarrhea, fatigue,
and rash, with a small percentage of patients experiencing the more
serious side effects of bleeding or atrial fibrillation. Given our mission to
developsuperiorbiological alternatives toconventional chemotherapy, the
Alliance designed amulticenter phase 1 study of rituximab, lenalidomide,
and ibrutinib in previously untreated follicular lymphoma. Utilization
of a multitargeted approach against a cell surface marker, the tumor
microenvironment, and an intracellular signaling pathway, may improve
outcomes in this multiply relapsing disease.
Methods
Eligibility criteria
Patients had previously untreated, histologically confirmed, World Health
Organization classification grades 1, 2, or 3a follicular lymphoma, based on
central review. Other inclusion criteria included age $18 years; Lugano
classification bulky stage II (mass$7 cm), III, or IV; and Eastern Cooperative
Oncology Group performance status of 0, 1, or 2. Patients must have had
measurable disease (mass .1 cm) and a clinical indication for treatment at the
discretionof their primary oncologist. Required initial laboratory values included
an absolute neutrophil count (ANC) $1000/mL, platelet count $75 000/mL,
serum creatinine #2 times the institutional upper limit of normal (ULN),
estimated creatinine clearance.60mL/min, total bilirubin#1.5 timesULN, and
aspartate aminotransferase (AST) and alanine transaminase (ALT) #2.5 times
upper ULN. Patients with low (0-1), intermediate (2), and high (.3) follicular
lymphoma international prognostic index (FLIPI) risk scores were permitted.
Exclusion criteria includedprior or concurrent chemotherapy, immunotherapy,
radiation therapy,or investigationalagents for the treatmentof follicular lymphoma;
corticosteroidswithin2weeks before study entryunless asmaintenance therapy for
a nonmalignant condition, or known central nervous system involvement.
Prohibited concomitant medications included strong inhibitors or inducers of
CYP3A4/5 and vitamin K antagonists. Alternative anticoagulants were permis-
sible. Other exclusion criteria included pregnancy; lactation; active hepatitis B
(HBV), hepatitis C, or HIV; active hemolysis; and severe cardiac conditions
including uncontrolled arrhythmia, congestive heart failure, myocardial infarction,
deepvenousorarterial thrombosiswithin6months, andClass III/IVcardiacdisease
as per New York Hospital Association Functional Classification. Patients with
previously diagnosed malignancies were excluded unless treated with curative
intent.3 years before screening and felt to be at a low risk of recurrence or had
adequately treated nonmelanomatous skin cancer, lentigo maligna melanoma, or
cervical carcinoma in situ without current evidence of disease.
Study design
This phase 1 study used a standard 313 dose escalation design. Rituximab 375
mg/m2 was administered IV on days 1, 8, 15, and 22 of cycle 1 and on day 1 of
cycles 4, 6, 8, and 10. Lenalidomidewas administered orally as per cohort dose on
days 1 to 21 for eighteen 28-day cycles. Ibrutinib was administered orally as per
cohort dose daily until progression or unacceptable toxicity (Figure 1). Patient
enrollment began at dose level (DL) 0 (lenalidomide 15mg and ibrutinib 420mg)
andescalated toDL2(lenalidomide20mg, ibrutinib560mg).Themaximumdose
of lenalidomide was chosen based on efficacy and tolerability in previous front-
line combination studies with rituximab in follicular lymphoma.5,6 Ibrutinib
560 mg is the recommended phase 2 dose (RP2D) for investigation in NHL.7,8
Allopurinol 300 mg daily was recommended for tumor lysis prophylaxis
with the initiationof therapy, andwasdiscontinuedat thediscretionof the treating
physician. Aspirin was recommended for deep venous thrombosis prophylaxis
while receiving lenalidomide. The use of low-molecular-weight heparin was
recommended for patients felt to be at a significantly increased risk for venous
thromboembolism in addition to aspirin. Granulocyte colony-stimulating factors
were restricted to patients who had febrile neutropenia. The use of erythropoietin
was not permitted. HBV-suppressive therapy was required for patients with
evidence of prior HBV infection. While receiving lenalidomide, female patients
of childbearingpotentialwere required to use2 formsof contraceptionor practice
abstinence in addition to being monitored with pregnancy tests each cycle.
Dose-limiting toxicity (DLT) assessments were performed weekly during
cycle 1. Nonhematologic DLTs were defined as any grade 3 or 4 toxicity, any
grade Stevens-Johnson syndrome or toxic epidermal necrolysis, grade 3-4
bullous dermatitis, andASTorALT$33ULNwith total bilirubin$23ULN.
Exceptions included grade 3 or 4 fatigue, anorexia, nausea, fever without
neutropenia, or tumor lysis that resolved to baseline after a 2-week treatment
delay. Because of the known incidence of rash with lenalidomide, grade 3 rash
that resolved to less than grade 2within 10 days was prospectively excluded as a
DLT. Patients may have received supportive care including systemic
corticosteroids. A limitation was not set for dosage or duration of corticosteroid.
Hematologic DLTs included any grade 4 toxicity (except grade 4 neutropenia
lasting,7days), grade3neutropeniawith fever$38.5°Cor infection, andgrade
2 or 3 thrombocytopenia complicated by hemorrhage.
Dosemodifications anddelayweremandatedper protocol for specific adverse
events. For grade 3 or 4 neutropenia, febrile neutropenia, or grade 3 or 4
thrombocytopenia, treatment with lenalidomide and ibrutinib was interrupted
and resumed at one dose level belowwith the following cycle if toxicity improved
to# grade 2. For grade 3 or 4maculopapular rash, treatment was interrupted and
resumed with one dose level reduction when improved to less than or equal to
grade 1. Supportive care, including systemic corticosteroids, was permitted
without duration or dosage limitations. Study drugs could be held for amaximum
of 28 consecutive days for toxicity. Study drugs believed to be responsible for a
prolonged toxicity were discontinued in the event of a toxicity lasting.28 days.
Patients underwent a PET-CT scan and bone marrow biopsy at enrollment
for initial staging assessment. Response assessments were classified per the
International Harmonization Project (IHP) on Lymphoma, which was the
standard at the timeof study initiation.11Assessmentsweredeterminedby the site
principal investigator and confirmedby the lead principal investigator. Restaging
PET-CT scans were performed at weeks 10, 24, and 52, after which patients
underwentCTscansevery4months for 2years, followedbyevery6monthsuntil
progression for 10 years. Bonemarrow biopsies were performed in patients who
were felt to be in a complete remission and hadmarrow involvement at baseline.
The study was approved by the ethics committee and institutional review
board at all participating cancer centers. Each patient provided written informed
consent in accordance with federal and institutional guidelines. The study was
registered with ClinicalTrials.gov (NCT01829568). Data collection and
statistical analyses were conducted by the Alliance Statistics and Data Center.
Data qualitywasmaintainedby theAllianceStatistics andDataCenter andby the
study chairperson following Alliance policies. All analyses were based on the
study database frozen on April 11, 2016.
Pharmacokinetic blood sampling schedule, measurement of
plasma ibrutinib, and PCI-45227 concentrations and
pharmacokinetic data analysis
Blood sampling schedule. Venous blood samples (2 mL into EDTA tubes)
were obtained preibrutinib (time 0) and at times up to 24 hours postibrutinib
dosing on cycle 1, days 1 and 15. The collected blood samples were processed
promptly at 0-4°C and plasma separated, frozen, and stored at 280 °C until
analyzed for ibrutinib and PCI-45227 concentrations.
Measurement of plasma ibrutinib and PCI-45227 concentrations.
Plasma concentrations of ibrutinib and PCI-45227 were determined using a
validated and specific high-performance liquid chromatography coupled to
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tandem mass spectrometry (HPLC-MS/MS) method. The lower limit of
quantitation (LLOQ) and the precision (%CV) of the assay in human plasma
were 0.5 ng/mL and,11%, respectively.12
Pharmacokinetic data analysis. Plasma ibrutinib and PCI-45227
concentration-time profiles were initially inspected on a log-linear plot and
analyzed using noncompartmental methods (WinNonLn Pro software). The
primary pharmacokinetic parameters, observed peak concentration (Cmax), and
time to reach themaximum concentration (Tmax), estimated elimination half-life
(T1/2), area under the plasma concentration-time curve from time 0 to 24 hours
(AUC(0-24)), and accumulation factor R (based on AUC) were defined where
adequate data points were available.
Statistical considerations
The primary objective was determining the recommended phase 2 doses (RP2D),
also called the maximally tolerated dose (MTD), of lenalidomide and ibrutinib in
combination with rituximab in previously untreated follicular lymphoma.
Secondary objectives included safety, pharmacokinetics, and preliminary efficacy
data.Once theMTDwasdetermined,using the traditional313cohortmethodwith
apotential dosede-escalation, therewas a10-patient expansion cohort at theMTD.
Patient characteristics were summarized using contingency tables for
categorical variables; median and range were calculated for continuous variables.
Toxicity (attributeandgrade)was summarized for the total numberofpatients, and
each dose level as per the National Cancer Institute (NCI) CommonTerminology
Criteria for Adverse Events (CTCAE), version 4.03. The observed ORR and CR
rates were calculated overall, within dose level, and by FLIPI score. ORR was
defined as CR 1 partial response (PR). Progression-free survival (PFS) was
defined as the time from registration until disease progression or death, whichever
occurredfirst.Overall survival (OS)was defined as the time from registration until
death. PFS and OS were estimated using the Kaplan-Meier method for the entire
study population as well as at the recommended phase 2 dose.13
Results
Patient characteristics
Twenty-two patients were enrolled between June 2013 and August 2014
at 7 Alliance participating cancer centers. Patient characteristics are
displayed inTable1.Themedianagewas53.5years (range,36-81).Sixty-
eight percent were male, 27% hadWHO classification grade 3a follicular
lymphoma, and 77% had stage IV disease. The majority of patients had
.4 nodal sites of disease involvement (64%) and bone marrow
involvement (77%). Fifty percent of patients had a lymph node .5 cm
in one dimension, and 27% had a node $7 cm. By FLIPI, 18% were
considered low risk, 55%were intermediate risk, and 27%were high risk.
Primary objective
Patients were treated at DL0 (n5 3), DL1 (n5 3), and DL2 (n5 16).
There were no protocol-defined dose-limiting toxicities reported at any
Rituximab 375 mg/m2 x 8 doses
1Cycle
(28 days)
2 3 4 5 6 7 8 9 10 11 18 19 Progressive Disease
Lenalidomide Days 1-21 for 18 cycles
Ibrutinib daily until progression
Dose Level Cohorts
Dose Level Lenalidomide Ibrutinib
Level -2 5 mg 280 mg
Level -1 10 mg 420 mg
Level 0 15 mg 420 mg
Level 1 15 mg 560 mg
Level 2 20 mg 560 mg
Figure 1. Dosing schema.
Table 1. Patient characteristics
Overall
N 5 22 (%)
Median age, y (range) 53.5 (36-81)
Sex
Male 15 (68%)
Female 7 (32%)
Stage
II 1 (5%)
III 4 (18%)
IV 17 (77%)
WHO classification grade
I/II 16 (73%)
IIIa 6 (27%)
ECOG performance score
0 13 (59%)
1 9 (41%)
FLIPI score
Low risk 4 (18%)
Intermediate risk 12 (55%)
High risk 6 (27%)
Nodal sites
#4 sites 8 (36%)
.4 sites 14 (64%)
Nodal size
$5 cm 11 (50%)
$7 cm 6 (27%)
ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma
International Prognostic Index; WHO, World Health Organization.
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dose level. Therefore, DL2 was determined to be theMTD and RP2D:
lenalidomide 20 mg days 1 to 21 for eighteen 28-day cycles, ibrutinib
560 mg daily until progression.
Adverse events
Hematologic and nonhematologic adverse events are displayed in
Tables 2 and 3, respectively. The most common grade 1 and 2
hematologic adverse eventswere anemia (27%) and thrombocytopenia
(23%); the most common grade 3 and 4 hematologic adverse event
was neutropenia (18%). The most common all-grade nonhematologic
adverse events were rash (82%), diarrhea (64%), and fatigue (59%).
Therewereno incidencesofbleeding, thrombosis, or tumorflare.Grade
3 nonhematologic adverse events included rash (36%), diarrhea (5%),
febrile neutropenia (5%), atrial flutter (5%), and arthralgia (5%). There
were no grade 4 nonhematologic adverse events reported. New malig-
nancieswere reported in 5 patients: recurrent squamous cell carcinoma
of the skin, melanoma in situ in an unusual mole that was being
monitored closely before enrollment, prostate cancer in a patientwith a
history of an elevated prostate-specific antigen, endometrial carci-
noma, and a poorly differentiated carcinoma. All malignancies were
diagnosed within the first year of therapy.
A total of 18 of 22 patients developed a rash with the regimen.
Rashes were primarily maculopapular in nature, with exception of 1
pustular rash. Grade 1 or 2 rash occurred in 46% of patients, whereas
grade 3 rash occurred in 36% of patients. Onset was typically during
cycle 1, but occurred as late as cycle 4. Grades 1 and 2 rash resolved
spontaneously without dose modification. Grade 3 rashes occurred
at each dose level (Table 4). Grade 3 rashes that occurred during
cycle 1 resolved within 10 days and were therefore not considered
dose-limiting toxicities. Patients were treated with acetaminophen,
diphenhydramine, and/or oral corticosteroids, and required treat-
ment delay and dose level reduction as per protocol guidelines.
Sulfamethoxazole/trimethoprim, prescribed for a urinary tract in-
fection, was considered to be the etiology of grade 3 rash in 1 patient.
Discontinuation of the antibiotic resulted in complete resolution
of the rash, and the patient did not require any dose modifications.
Shortly after study commencement, given that rash was being ob-
served commonly, allopurinol was only used per investigator
discretion for patients felt to be at high risk for tumor lysis syndrome.
Ten of the 11 patients who received allopurinol developed a rash;
however, 8 of the 11 patients who did not receive allopurinol also
developed a rash. Two patients withdrew from the study because of
persistent rashes that occurred after cycle 1. One of these patients
underwent a biopsy of the rash, which showed findings consistent
with a drug-induced erythrodermic hypersensitivity reaction, charac-
terized by lymphocytic infiltration and scattered eosinophils.
Treatment modifications
Twenty patients completed 6 cycles of rituximab, 10 patients completed
18 cycles of lenalidomide, and 9 patients continued to receive single-
agent ibrutinib.Themedian timepatients received ibrutinibmonotherapy
was 8 cycles (3-151). Patients received 90% of the expected dose
intensity of rituximab, 64% of lenalidomide, and 93% of ibrutinib. The
dose intensity of rituximab and lenalidomidewas calculated based on the
planned duration of treatment of each agent. Because ibrutinib was to be
administered indefinitely, the dose intensity of ibrutinib was calculated
based on the number of cycles the patient received therapy in the study.
Eleven patients (50%) from all dose levels required dose reduction
because of adverse events: rash (n 5 7, 32%), neutropenia (n 5 3,
14%), thrombocytopenia (n51,5%).Sixpatients discontinued therapy
because of adverse events including grade 3 rash (n 5 2, 9%), grade
3 atrial flutter (n5 1, 5%), grade 3 diarrhea (n5 1, 5%), hypertension
(n5 1, 5%), and depression (n5 1, 5%). The patients who developed
an endometrial carcinoma and a poorly differentiated carcinoma
required alternative interventions for their newly diagnosed malignan-
cies, prompting study withdrawal.
Pharmacokinetics
Pharmacokinetic analyses were performed on plasma ibrutinib and its
most potent metabolite, PCI-45227 concentrations, from data available
in as many as 7 patients: DL0 (n 5 2), DL1 (n 5 3), DL2 (n 5 2).
Ibrutinib demonstrated rapid absorption with a median time to
maximum concentration (Tmax) of 1 hour (range, 1-4). The median
Cmax was 98.2 ng/mL (range, 15.4-354.0) and median AUC (0-24) was
669.5 ng.h/mL (range, 191.3-2072.2). Themedian elimination half-life
was 6.9 hours (range, 4.1-8.9). There was minimal accumulation of
ibrutinib by day 15. The R factor (based onAUC)was amaximum1.3.
ThePCI-45227/ibrutinibAUC(0-24) ratio at steady state ranged from0.9
to 3.1. Ibrutinib pharmacokinetic disposition when co-administered
with lenalidomide and rituximab was consistent with that described for
ibrutinib monotherapy at the doses studied.14,15
Efficacy
The ORR for the entire cohort of patients was 95%. Thirty-six percent
(n 5 8) of patients achieved CR (Table 5). An additional 7 patients
(32%) experienced resolution of hypermetabolic activity on PET-CT
consistent with a CR, but did not undergo a confirmatory bonemarrow
biopsy to rule out residualmarrow involvement. All of the patientswith
pretreatment marrow involvement who achieved PET negativity and
underwent trephine biopsy were found to have resolution of disease
Table 2. Hematologic adverse events
All grades Grade 1 Grade 2 Grade 3 Grade 4
Neutropenia 36% 9% 9% 9% 9%
Thrombocytopenia 33% 23% 5% 5% 0%
Anemia 32% 27% 0% 5% 0%
Lymphopenia 23% 18% 0% 5% 0%
Table 3. Nonhematologic adverse events
All grades Grade 1 Grade 2 Grade 3 Grade 4
Rash 82% 41% 5% 36% 0%
Diarrhea 64% 50% 9% 5% 0%
Fatigue 59% 45% 14% 0% 0%
Infusion-related reaction 37% 14% 23% 0% 0%
Nausea 32% 32% 0% 0% 0%
Infection 28% 5% 23% 0% 0%
Neoplasms 23% 0% 5% 18% 0%
Arthralgia 19% 14% 0% 5% 0%
Hyperbilirubinemia 19% 14% 5% 0% 0%
ALT increased 19% 14% 5% 0% 0%
AST increased 18% 18% 0% 0% 0%
Headache 18% 18% 0% 0% 0%
Constipation 14% 14% 0% 0% 0%
Edema 14% 9% 5% 0% 0%
Fever 14% 5% 9% 0% 0%
Creatinine increased 9% 9% 0% 0% 0%
Neuropathy 9% 9% 0% 0% 0%
Hyperuricemia 9% 9% 0% 0% 0%
Atrial flutter 5% 0% 0% 5% 0%
Periorbital edema 5% 0% 0% 5% 0%
Febrile neutropenia 5% 0% 0% 5% 0%
ALT, alanine transaminase; AST, aspartate transaminase.
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(n5 4). The response rates at the RP2D were similar: ORR 94% and
CR 38%. The ORR by FLIPI risk group were 100% in low (n 5 4),
100% in intermediate (n5 12), and 83% in high (n5 5). One high-risk
patient maintained stable disease with the regimen. Themedian time to
first response was 2.3 months (1.9-11.1), and the median time to best
response was 5.5 months (1.9-25.1). Two patients chose to withdraw
from the study after achieving CR. One remains in CR 9 months after
discontinuing therapy, and the other was lost to follow-up.
At a median follow-up of 19.2 months (2.3-27.1), the 12-month PFS
was 80% (95% confidence interval [CI], 57%-92%) (Figure 2). Four
patients progressedwhile receiving treatment during cycles 6, 12, 17, and
18.Onepatient progressedduringcycle 3during a2-week treatment delay
forgrade3 rash.Onepatient progressed1monthafterwithdrawal fromthe
study after cycle 13 for a diagnosis of endometrial carcinoma.None of the
8 other patients who discontinued therapy early have experienced a
progressionof follicular lymphoma.Thepatient found tohaveametastatic
poorly differentiated carcinoma died 1month after studywithdrawal. The
remaining patients were still alive at the time of the final analysis.
Discussion
Alliance A051103 is the first clinical investigation of the combination
of rituximab, lenalidomide, and ibrutinib. This single-arm, phase 1 trial
expanded upon our prior experience with the rituximab-lenalidomide
doublet in follicular lymphoma (CALGB 50401, CALGB 50803)
by incorporating the use of a third distinct novel agent, ibrutinib.
A051103 implemented similar inclusion criteria to previous frontline
chemoimmunotherapy studies (FOLL05, PRIMA, NHL-2, BRIGHT),
including advanced-stage patients, all FLIPI prognostic groups, and a
clinical indication for treatment. Although a significantly smaller study,
the triplet demonstrated efficacy comparable with traditional cytotoxic
regimens (ORR 95%, CR 36%).1-4,6,7 Although the CR rate appeared
lower thanwithpreviously reported regimens, nearly50%of thepatients
who achieved PET negativity did not undergo confirmatory bone
marrow biopsy andwere not included in the reported value. Because all
of the patients who had a follow-up biopsy per protocol were noted to
have resolution of marrow involvement, it is possible that the true CR is
as high as 68%. Responses were independent of FLIPI score and bulky
disease, further supporting the consideration of biological regimens for
the treatment of follicular lymphoma.
Although there were no protocol-defined, dose-limiting adverse
events, the regimen was associated with clinically significant rash (all
grades, 82%; grade 3, 36%). Rash occurred more frequently than
reported with rituximab-lenalidomide (40%-58%, 7%-8%) or
rituximab-ibrutinib (27%, 5%) in upfront follicular lymphoma or
single-agent ibrutinib (25%, 3%-4%) and lenalidomide-ibrutinib (32%,
14%) in relapsed B-cell malignancies.6,7,15-17 Although line of therapy
and disease histology may have affected the incidence and degree of
rash, severe rashoccurred at all dose levelswith the triplet in this setting,
prompting dose reduction in 7 patients andwithdrawal from study in 2.
One of the limitations of the study was the mandated reduction in dose
per protocol, which may have affected depth of response. The depth of
response, however, cannot be accurately evaluated because 7 patients
who achieved a PET negativity did not undergo a confirmatory bone
marrow biopsy. It may have been possible for at least some patients to
continue at the same dose level with supportive care as has previously
been demonstrated with single-agent lenalidomide. Although there is a
shortmedian follow-up, the durability of the regimen does not appear to
be significantly compromised by the dose modifications thus far.
Confounding factors including concomitant medications were
analyzed as potential etiologies for rash. Allopurinol was considered
to be a culprit; however, a similar proportion of the patients who did not
receive it also developed a rash. Aside from the use of a sulfa-based
antibiotic in one patient, there were no other identifiable causes. The
interaction between the monoclonal antibody, immunomodulatory
agent, and BTK inhibitor appears to have triggered an undefined
immune reaction, specific to follicular lymphoma. Preliminary un-
published data from a phase 1 study of the triplet in relapsed and
refractory CLL do not suggest the same dermatologic toxicity profile
(C.S.U., unpublished data; NCT02160015). Interestingly, the addition
of a PI3 kinase antagonist, idelalisib, to rituximab-lenalidomide resulted
in a higher degree of immune activation as is evident by 2 Alliance
studies in relapsed follicular lymphoma and mantle cell lymphoma
(A051201, A051202). Both trials were terminated early because of the
development of an adverse event similar to a cytokine release syndrome,
characterizedby fever, hypotension, and rash.18Preclinical studiesof the
combination of the 3 agents in this study had not been performed.
Greater investigation into the effect of biological combinations on the
malignant lymphocyte, tumor microenvironment, and additional
targets, is necessary in understanding these types of outcomes.
Given the significantly increased financial cost of this and similar
Table 4. Incidence of rash by DL
All patients (n 5 22) DL 0 (n 5 3) DL 1 (n 5 3) DL 2 (n 5 16)
All grades 82% 100% 67% 81%
Grade 1/2 46% 67% 33% 44%
Grade 3/4 36% 33% 33% 38%
Definitions based on NCI CTCAE criteria, version 4.03: Grade 1: ,10% body
surface area (BSA) involved; Grade 2: 10-30% BSA involved, limiting instrumental
activities of daily living (ADLs); Grade 3: .30% BSA involved, limiting self-care ADLs).
Table 5. Response rates by DL
Response All patients (n 5 22) DL 0 (n 5 3) DL 1 (n 5 3) DL 2 (n 5 16)
ORR 95% 100% 100% 94%
CR 36% 33% 33% 38%
PR 59% 67% 67% 56%
SD 5% 0 0 6%
CR, complete response; ORR, overall response rate; PR, partial response; SD,
stable disease.
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Figure 2. Progression-free survival.
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multitargeted novel agent regimens compared with chemo-
immunotherapy, strong scientific rationale for future studies is vital.
Compared with the frontline CALGB 50803, there appeared to be a
greater incidence of grades 1-4 diarrhea (59% vs 33%) and arthralgia
(19% vs 0), both of which are known adverse effects of ibrutinib. One
patientwithdrew from the study because of a persistent grade 3 diarrhea,
which developed 2 years after study enrollment, suggesting that delayed
toxicity canbe seenwithBCRantagonists. Similarly, therewere ahigher
number of newmalignancies (5vs 0)with shorter follow-up.Although3
patients had risk factors and all diagnoseswere identifiedwithin ayear of
initiation of therapy, a potential correlation between the regimen and an
accelerated development of malignancy remains possible. There were
fewer thrombotic events than in CALGB 50803 (0 vs 3) or the relapsed
population in CALGB 50401 (0 vs 2), which may have been related to
the antiplatelet properties of aspirin and ibrutinib or merely smaller
sample size. Notably, there were no bleeding events either, which may
reflect the thrombogenic nature of lenalidomide.
Response data at dose level 2 appeared similar to CALGB 50803,
but an accurate comparison of PFS is not yet possible given the shorter
median follow-up. Other limitations of the study include small sample
size and the lack of repeat bone marrow biopsies in some patients to
confirm CR. Regardless, an improvement in clinical benefit with the
additional third agent was not apparent. Increased toxicity and required
dose modifications, including a 50% early discontinuance rate, is
unacceptable for a frontline follicular lymphoma regimen. Although
further investigation of the triplet seems unwarranted in this setting, the
rituximab-lenalidomide combination remains a promising option. The
RELEVANCE study will ultimately establish whether the biological
doublet has a role as a frontline regimen for follicular lymphoma, and
the AUGMENT study is evaluating this approach in the relapsed
population. Ibrutinibmay have a place in the relapsed setting as a single
agent or in combination with another biological agent; however, better
predictive markers are necessary given modest single-agent response
rates in this population. As the treatment algorithm for follicular
lymphoma continues to evolve, the rational incorporation of biological
therapies is crucial in tailoring a safe, effective regimen for each patient.
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